4D Molecular Therapeutics has announced positive 52-week results from its phase 2b PRISM trial evaluating 4D-150 for wet age-related macular degeneration (AMD). The therapy, designed to provide sustained anti-VEGF expression through a single intravitreal injection, significantly reduced the need for supplemental injections while maintaining visual acuity.

Among patients receiving a 3E10 vg/eye dose, there was an 83% reduction in supplemental injections compared to standard aflibercept treatment. In a subgroup of recently diagnosed patients, 87% required no more than one injection over the 52-week period, and 80% remained injection-free.

The treatment has been well tolerated in clinical trials, with no serious safety concerns reported. 4DMT plans to initiate a pair of phase 3 trials, 4FRONT-1 and 4FRONT-2, in 2025; these will test the 3E10 vg/eye dose. Primary endpoint data from these studies are expected in 2027. RP